Eversource Energy is set to raise $1.5 billion from selling its first hybrid bonds, as the New England utility operator looks to refinance debt. The 30.5-year securities are being offered in two $750 million parts, according to a person with knowledge of the matter. One of the bonds can’t be bought back for 5.25 years, and the other not for 10.5 years, said the person, who asked not to be identified as they’re not authorized to speak publicly. The notes are poised to respectively yield 6.1% and 6.35%, both about 0.4 percentage point less than initial price talk, the person added. Hybrid bonds have features of both debt and equity. They’ve grown more popular in recent years, particularly among utility holding companies , after a change in policies from Moody’s Ratings made it easier for corporations to determine how much equity-like credit they would get for selling the securities. Barclays Plc, Bank of America Corp., Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley and Mitsubishi UFJ Financial Group Inc. are bookrunners for the debt sale. The deal is among 10 in the US investment-grade market on Monday — half of them from utilities.

Former British ⁠ambassador to the US Peter Mandelson has been arrested by London police on suspicion of misconduct in public office, following revelations over his ties to convicted sex offender Jeffrey ‌Epstein. Mandelson, 72, was fired from the most prestigious posting in Britain’s diplomatic service in September, when the depth of his friendship with Epstein started to become clear. Police earlier this month began a criminal investigation into Mandelson after Prime Minister Keir Starmer’s...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

In trading on Monday, shares of EOS Energy Enterprises Inc (Symbol: EOSE) crossed below their 200 day moving average of $10.19, changing hands as low as $10.01 per share. EOS Energy Enterprises Inc shares are currently trading down about 5.3% on the day. The chart below shows

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

格隆汇2月24日｜俄罗斯国防部：俄防空系统五小时击落45架乌克兰无人机。

格隆汇2月24日｜澳元兑美元AUD/USD日内跌幅达0.50%，现报0.7048。

Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and main sales generator), Anktiva, grew sales by 700% in 2025, and delivered 20% quarter-over-quarter growth in Q4. While earnings per share remained negative at $0.06 in Q4, it was the third straight quarter of profitability improvement as Anktiva rapidly expands. Following today's rise on ImmunityBio's solid earnings, the stock has already roughly quintupled in 2026 as it continues to reel off positive news. Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of cancers and diseases. While the bulk of ImmunityBio's business currently comes from U.S. sales of Anktiva, a treatment for bladder cancer cases that did not respond to the Bacille Calmette-Guérin (BCG) vaccine, the company is rapidly expanding. Image source: Getty Images. Continue reading

Palantir Technologies Inc. stock price snapshot Florida Today

Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda. (Source: Bloomberg)

In trading on Monday, the iShares U.S. Pharmaceuticals ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Eyepoint, up about 5.4% and shares of Ocular Therapeutix, up about 5% on the day. And underper

Exchange Income Corp. , which acquires and operates aerospace, aviation and manufacturing businesses, is preparing to sell as much as C$500 million ($365 million) of bonds in its first note sale, according to people familiar with the matter. The Winnipeg, Canada-based firm is looking at debt that matures in five or seven years, the size of the deal could range from C$300 million to C$500 million, said the people, who asked not to be identified as they aren’t authorized to speak publicly. The firm received a BBB (low) issuer rating with a stable trend from Morningstar DBRS last week. The lowest investment grade rating reflects its “well-established lines of services, albeit limited to niche markets,” according to DBRS analysts. Exchange Income Corp.’s businesses provide services and goods ranging from air ambulance to defense sector components. Executives are due to speak with investors on Wednesday, Bloomberg reported last week. A bond sale could come as soon as this week, the people said. Representatives did not immediately respond to a request for comment.

President Donald Trump is expanding his tariff toolkit in the wake of a Supreme Court ruling against his signature economic policy.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me

In trading on Monday, apparel stores shares were relative laggards, down on the day by about 5.5%. Helping drag down the group were shares of Stitch Fix, off about 9.2% and shares of American Eagle Outfitters off about 9% on the day. Also lagging the market Monday are textiles

asbe/iStock via Getty Images By Ezequiel Gomes Silver ( XAGUSD:CUR ) pushed sharply higher this Monday as traders tracked a fresh surge in haven demand tied to rising U.S.-Iran tensions and new uncertainty around U.S. trade policy. This mix also kept currency markets jumpy and amplified moves across precious metals. Market snapshot Silver was last around $87.28, extending a powerful rebound that has been defined by wide daily ranges rather than steady step-by-step gains. The day’s range mattered as much as the level. Trading data showed silver moving between about $84.39 and $87.87, a band that underscores how quickly liquidity and sentiment have been flipping in late-February trade. Silver price dynamics (January - February 2026) (Source: TradingView) In the broader complex, precious metals moved higher together, with silver outperforming as investors leaned into protection trades and shorter-term momentum strategies. Drivers traders cited: risk headlines, tariffs, and FX Geopolitical risk remained a primary catalyst. Markets kept a close watch on developments tied to U.S.-Iran tensions, which have periodically lifted demand for defensive assets and widened price reactions in metals. Trade policy uncertainty added a second layer. A U.S. Supreme Court ruling on tariffs, followed by renewed tariff announcements and legal questions, fed a “policy risk premium” that helped support havens and kept cross-asset correlations unusually tight. Foreign exchange moves also mattered because silver is dollar-priced. The dollar’s response to the court decision and subsequent headlines shaped how aggressively non-U.S. buyers and macro funds were willing to add exposure into strength. What comes next: Rates calendar and key levels Even with geopolitics in the driver’s seat, traders still treated rates as the gatekeeper for durability. If yields stay firm, rallies can struggle to hold; if yields ease, silver tends to keep more of its gains after the initial headline impulse. This we...

With the right approach, you can make that money last.

Here's Why Oracle Stock Slumped Today The Motley Fool

In trading on Monday, cigarettes & tobacco shares were relative leaders, up on the day by about 2%. Leading the group were shares of Ispire Technology, up about 9% and shares of Altria Group up about 1.6% on the day. Also showing relative strength are precious metals share

Reiner, 32, charged with two counts of first-degree murder after parents were stabbed to death in December Nick Reiner pleaded not guilty to two counts of first-degree murder in the killing of his parents Rob Reiner and Michele Singer Reiner. His new attorney, public defender Kimberly Greene, entered the plea during arraignment in the case on Monday morning, while Reiner was behind glass in the Los Angeles courtroom. Continue reading...

Earnings Call Insights: GeneDx Holdings Corp. (WGS) Q4 2025 Management View Katherine Stueland, President and CEO, indicated that "the fourth quarter was a strong finish to a transformative year for GeneDx," reporting quarterly revenues of $121 million and full year revenues of $428 million, with 54% exome and genome revenue growth. She emphasized, "2026 is going to be a breakout year for GeneDx," highlighting the company's leadership in rare disease diagnostics, bolstered by a recent FDA breakthrough device designation. Stueland described Infinity, the company's rare disease data set, as "the world's largest and most diverse rare disease data set," and outlined the expansion into new markets, including general pediatrics, NICU, prenatal, adult specialists, and international. Stueland shared that the company is "nearly tripling what was already the largest sales force in rare disease to capture the wide open space ahead of us," expanding from approximately 50 reps in 2025 to 75 in 2026 for foundational markets, plus dedicated teams for general pediatricians, NICU, prenatal, adults, and international markets. Kevin Feeley, CFO, stated, "For the fourth quarter, total revenues were $121 million, up 27% year-over-year. Within that though, exome and genome revenues were $104 million, an increase of 32% year-over-year." Feeley cited an average reimbursement rate for exome and genome of $3,750 in Q4, with a company-wide adjusted gross margin of 71% for the quarter and full year. He explained, "Full year 2023 gross margin was 45%, which went up to 65% in 2024 and now 71% in 2025." Outlook Feeley reaffirmed, "we're reaffirming our guidance to include total revenues in the range of $540 million to $555 million, exome and genome volume growth of 33% to 35% with a baseline of 33% growth for Q1." He broke down expected contributions: foundational markets to deliver 25% to 27% of growth, expansion markets 7% to 8%, and future markets about 1%. He added, "We're expecting adjusted ...

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Oracle is now the #64 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each bro